-
Solving clinical trial delays: innovative solutions
Kavita Singh, M Abdul Salam, Raji Devarajan & Dorairaj Prabhakaran
Clinical Trail Perspective: Clinical Investigation
-
Solving clinical trial delays: innovative solutions
Kavita Singh, M Abdul Salam, Raji Devarajan & Dorairaj Prabhakaran
Clinical Trail Perspective: Clinical Investigation
-
Solving clinical trial delays: innovative solutions
Kavita Singh, M Abdul Salam, Raji Devarajan & Dorairaj Prabhakaran
Clinical Trail Perspective: Clinical Investigation
-
Solving clinical trial delays: innovative solutions
Kavita Singh, M Abdul Salam, Raji Devarajan & Dorairaj Prabhakaran
Clinical Trail Perspective: Clinical Investigation
-
Solving clinical trial delays: innovative solutions
Kavita Singh, M Abdul Salam, Raji Devarajan & Dorairaj Prabhakaran
Clinical Trail Perspective: Clinical Investigation
-
Solving clinical trial delays: innovative solutions
Kavita Singh, M Abdul Salam, Raji Devarajan & Dorairaj Prabhakaran
Clinical Trail Perspective: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 12
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 12
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 12
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 12
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 12
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 12
Acknowledgements: Clinical Investigation
-
South East Scotland Cancer Research Network: an opportunity to expand
Vivienne Wilson
Research Update: Clinical Investigation
-
South East Scotland Cancer Research Network: an opportunity to expand
Vivienne Wilson
Research Update: Clinical Investigation
-
South East Scotland Cancer Research Network: an opportunity to expand
Vivienne Wilson
Research Update: Clinical Investigation
-
South East Scotland Cancer Research Network: an opportunity to expand
Vivienne Wilson
Research Update: Clinical Investigation
-
South East Scotland Cancer Research Network: an opportunity to expand
Vivienne Wilson
Research Update: Clinical Investigation
-
South East Scotland Cancer Research Network: an opportunity to expand
Vivienne Wilson
Research Update: Clinical Investigation
-
Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Lucy Lee
Special Report: Clinical Investigation
-
Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Lucy Lee
Special Report: Clinical Investigation
-
Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Lucy Lee
Special Report: Clinical Investigation
-
Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Lucy Lee
Special Report: Clinical Investigation
-
Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Lucy Lee
Special Report: Clinical Investigation
-
Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Lucy Lee
Special Report: Clinical Investigation
-
Is there a future for CETP-inhibitor therapy?
Jennifer G Robinson
Editorial: Clinical Investigation
-
Is there a future for CETP-inhibitor therapy?
Jennifer G Robinson
Editorial: Clinical Investigation
-
Is there a future for CETP-inhibitor therapy?
Jennifer G Robinson
Editorial: Clinical Investigation
-
Is there a future for CETP-inhibitor therapy?
Jennifer G Robinson
Editorial: Clinical Investigation
-
Is there a future for CETP-inhibitor therapy?
Jennifer G Robinson
Editorial: Clinical Investigation
-
Is there a future for CETP-inhibitor therapy?
Jennifer G Robinson
Editorial: Clinical Investigation